Objectives. To find how many @entity6 should receive anti-aggregant treatment according to the recommendations made since 2001 by the American @entity6 Association (ADA), how many @entity65 could be avoided by 100 mg daily of @entity117 ( @entity1281 ), and the cost per event avoided by this measure. Design. Transversal, descriptive, multi-centre study.Setting. Primary care. 8 clinics in 5 health districts (3 rural, 1 semi-urban, 4 urban) in the Le  n area. @entity1 . @entity6 aged 14 or over diagnosed through the ADA criteria since 1997.Main measurements. Audit of clinical records, collecting age and sex, the presence of the criteria of the ADA for anti-aggregation, the existence of established @entity65 ( @entity65 ) and the anti-aggregant treatment @entity1 receive. Results. 544 @entity6 . 97.2% (95% CI, 95.8%-98.6%) comply with anti-aggregation criteria. 101 had established @entity65 (18.6%; CI, 15.3%-21.9%); 77.2% received anti-aggregants (CI, 73.7%-80.7%).428 had no @entity65 and did have anti-aggregation criteria (78.7%; CI, 75.3%-82.1%); 9.3% (CI, 6.9%-11.7%) received treatment.Conclusions. There was basically little follow-up of the ADA anti-aggregation recommendations in primary prevention. Treatment of our @entity6 with 100 mg/day of ASA would avoid 7.64 @entity65 in five years (CI, 5.56-9.72). The cost per cardiovascular event avoided was 6,625.37 @entity7634 (CI, 4821.60-8429.14 @entity7634 ).

[Use of anti-aggregant drugs in primary and secondary cardiovascular prevention in XXXX in town and country in the Le  n area].

@entity1 :: ('9606', 'Species') :: ['patients', 'Participants'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetics', 'Diabetics'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid'] @entity1281 :: ('CHEBI:15365', 'Chemical') :: ['ASA'] @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular events', 'cardiovascular disease'] @entity7634 :: ('9319', 'Species') :: ['euros']
@entity6 :: (MESH:D003920,Disease) :: ['diabetics']
